These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Azadpour M; Lamas GA Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434 [TBL] [Abstract][Full Text] [Related]
25. [Cardiovascular system drugs. 4/12. Enzyme conversion inhibitors]. Martin F; Limat S Soins; 2004 Jun; (686 Pt1):57-8. PubMed ID: 15326942 [No Abstract] [Full Text] [Related]
26. Factors to consider in selecting an angiotensin-converting-enzyme inhibitor. Waugh WJ Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S26-30. PubMed ID: 11030020 [TBL] [Abstract][Full Text] [Related]
27. Cardioprotection with angiotensin-converting enzyme inhibitors: redefined for the 1990s. Kloner RA; Przyklenk K Clin Cardiol; 1993 Feb; 16(2):95-103. PubMed ID: 8435934 [TBL] [Abstract][Full Text] [Related]
28. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998 [TBL] [Abstract][Full Text] [Related]
29. [Summary of seminar on renin-angiotensin system and angiotensin converting enzyme inhibitor]. Zhonghua Yi Xue Za Zhi; 1995 Feb; 75(2):70-3. PubMed ID: 7767770 [No Abstract] [Full Text] [Related]
30. Ramipril in the treatment of vascular diseases. Rokoss MJ; Teo KK Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510 [TBL] [Abstract][Full Text] [Related]
33. Angiotensin converting enzyme inhibition: from viper to patient. Komajda M; Wimart MC Heart; 2000 Sep; 84 Suppl 1(Suppl 1):i11-4:discussion i50. PubMed ID: 10956312 [No Abstract] [Full Text] [Related]
34. Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction. Poole-Wilson PA Arch Mal Coeur Vaiss; 1994 Jun; 87 Spec No 2():35-8. PubMed ID: 7864720 [No Abstract] [Full Text] [Related]
35. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Dinicolantonio JJ; Lavie CJ; O'Keefe JH Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903 [TBL] [Abstract][Full Text] [Related]
38. [Vasopeptidase inhibitors. Clinical implications of a new class of drugs]. Quaschning T; Corti R; Ruschitzka FT; Noll G; Lüscher TF Dtsch Med Wochenschr; 2000 Apr; 125(16):499-503. PubMed ID: 10819011 [No Abstract] [Full Text] [Related]
39. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. Jose P; Tomson C; Skali H; Rouleau J; Braunwald E; Arnold JM; Cuddy T; Sussex B; Bernstein V; Pfeffer M; Solomon S J Am Coll Cardiol; 2006 Apr; 47(8):1725-7. PubMed ID: 16631015 [No Abstract] [Full Text] [Related]
40. [Fosinopril in the cardiovascular management of elderly patients]. Fortschr Med Suppl; 1996; 175():1-8. PubMed ID: 9022409 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]